Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2016 09:00 ET | Source: Vaxil Bio Ltd.

Vaxil Announces Key US Patent and Trademark Office Notice of Allowance for Its Immunotherapy

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - August 04, 2016) - VAXIL BIO (TSX VENTURE: VXL),a biotechnology company specializing in immunotherapy, announces today that it has received a Notice of...
June 16, 2016 09:30 ET | Source: Vaxil Bio Ltd.

Vaxil Receives Positive Response From European Patent Office for the Allowance of the Immunotherapy Orphan Drug Designated ImMucin(TM)

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - June 16, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotech specializing in immuno-oncology, reports that it has successfully received a...
March 31, 2016 09:15 ET | Source: Vaxil Bio Ltd.

Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin(TM) Cancer Vaccine

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - March 31, 2016) - VAXIL BIO LTD. (TSX VENTURE: VXL), an Israeli biotechnology company specializing in cancer immunotherapy, is very...
March 10, 2016 09:30 ET | Source: Vaxil Bio Ltd.

Vaxil Becomes First Israeli Biotech to List on TSX-Venture

TORONTO, ON and REHOVOT, ISRAEL--(Marketwired - March 10, 2016) - Vaxil Bio Ltd. ("Vaxil" or the "Company") (TSX VENTURE: VXL) wishes to announce the closing of its go-public via reverse...